3 results
Approved WMOCompleted
Main objective of this project is to establish the maximum tolerable dose (MTD) and recommended phase II dose of intraperitoneal irinotecan in patients with PC of colorectal origin, added to standard of care systemic chemotherapy. Other endpoints…
Approved WMOPending
This study investigates the safety and efficacy of the new drug anifrolumab in patients with Lupus Nephritis. The effect of anifrolumab is compared with the effect of a placebo. Anifrolumab and placebo ("the study drug") are added to the…
Approved WMOPending
The objective of this study is to evaluate the clinical efficacy, biological effects and safety of anifrolumab treatment in pSS.